Evidence map›Paper›PMID 29020226›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Innate, T-, and B-Cell Responses in Acute Human Zika Patients.

Lilin Lai, Nadine Rouphael, Yongxian Xu, Muktha S Natrajan, Allison Beck, Mari Hart, Matthew Feldhammer, Amanda Feldpausch, Charles Hill, Henry Wu and 10 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Characterization of CD8Journal of virology · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Lilin LaiHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Nadine RouphaelHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Yongxian XuHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Muktha S NatrajanHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Allison BeckHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Mari HartHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Matthew FeldhammerDepartment of Pathology, School of Medicine, Emory University, Atlanta, Georgia.
Amanda FeldpauschGeorgia Department of Public Health, Emory University, Atlanta, Georgia.
Charles HillDepartment of Pathology, School of Medicine, Emory University, Atlanta, Georgia.
Henry WuEmory TravelWell Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Jessica K FairleyEmory TravelWell Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Pamela Lankford-TurnerHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Nicole KasherHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Patrick RagoDepartment of Pathology, School of Medicine, Emory University, Atlanta, Georgia.
Yi-Juan HuDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Srilatha EdupugantiHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Shital M PatelSection of Infectious Diseases, Departments of Medicine and Molecular Virology and Microbiology.
Kristy O MurrayPediatrics-Tropical Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston.
Mark J MulliganHope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur.
Emory Zika Patient Study Team
Emory University · USBaylor College of Medicine · US

Funding

Dengue Virus Infection in IndiaU01AI115651 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2015 to 2019
$4.0M
Association Tests of Rare Variants Using Sequence Reads without Calling GenotypesR01GM116065 · NIGMS · EMORY UNIVERSITY · PI HU, YIJUAN · 2015 to 2019
$1.5M
NIAID NIH HHS HHSN272201300018INIAID NIH HHS U01 AI115651NIGMS NIH HHS R01 GM116065
6 · The paper itself

Abstract

Background: There is an urgent need for studies of viral persistence and immunity during human Zika infections to inform planning and conduct of vaccine clinical trials. Methods: In 5 returned US travelers with acute symptomatic Zika infection, clinical features, viral RNA levels, and immune responses were characterized. Results: Two pregnant, flavivirus-experienced patients had viral RNA persist in plasma for >44 and >26 days. Three days after symptom onset, transient increases in proinflammatory monocytes began followed at 5 days by transient decreases in myeloid dendritic cells. Anti-Zika virus immunoglobulin M was detected at day 7 after symptom onset, persisted beyond 103 days, and remained equivocal through day 172. Zika virus-specific plasmablasts and neutralizing antibodies developed quickly; dengue virus-specific plasmablasts and neutralizing antibodies at high titers developed only in flavivirus-experienced patients. Zika virus- and dengue virus-specific memory B cells developed in both flavivirus-naive and -experienced patients. CD4+ T cells were moderately activated and produced antiviral cytokines after stimulation with Zika virus C, prM, E, and NS5 peptides in 4/4 patients. In contrast, CD8+ T cells were massively activated, but virus-specific cells that produced cytokines were present in only 2/4 patients assessed. Conclusions: Acute infections with Zika virus modulated antigen-presenting cell populations early. Flavivirus-experienced patients quickly recalled cross-reactive MBCs to secrete antibodies. Dengue virus-naive patients made little dengue-specific antibody but developed MBCs that cross-reacted against dengue virus. Zika virus-specific functional CD4+ T cells were readily detected, but few CD8+ T cells specific for the tested peptides were found.

Indexed as

Adaptive ImmunityImmunity, InnateAdultAntibodies, NeutralizingAntibodies, ViralB-LymphocytesFemaleHumansImmunoglobulin MMalePregnancyRNA, ViralTime FactorsT-Lymphocyte SubsetsViral LoadZika VirusAntibodies, NeutralizingAntibodies, ViralImmunoglobulin MRNA, Viralflavivirusimmunitypregnancyviral persistenceZika

Identifiers

PMID29020226
PMCPMC5850027
OpenAlexW2791927440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.